Nuke, you called out one of the main points from my diatribe (see last post) much more concisely. It is premature to say that the Avastin control arm was understating PFS by a couple months. My analysis showed that there was another large participation trial on elderly patients that gave PFS results similar to the control arm that PPHM observes in theirs.
There were four side-by-side technical papers on my desk when I penned that last post. Too much information being condensed down to meaningful take aways is always as challenge.
News 
Market Data 
Discover 
